Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome b5 type A pseudogene 3 (CYB5AP3, also referred to as Psgb-5-1) is annotated as a processed pseudogene within the cytochrome b5 family. Pseudogenes are DNA sequences resembling functional genes but are typically noncoding due to frame disruptions, mutations, or other sequence changes that prevent expression of functional proteins. CYB5AP3 is distinct from the protein-coding gene cytochrome b5 type A (CYB5A), which encodes a membrane-bound hemoprotein functioning as an electron carrier for membrane-bound oxygenases. While some pseudogenes may participate in regulatory noncoding RNA functions, most are not considered direct therapeutic targets, receptors, enzymes, or transporters. CYB5AP3 is not a protein-coding gene, nor is it a validated therapeutic target or functional receptor/enzyme. This locus is characterized as a pseudogene of the cytochrome b5 type A gene family and lacks evidence of biological activity as a molecular target. There is no evidence it encodes a protein or acts as a receptor/enzyme, and it has no established roles in drug interaction or disease causality. It should not be conflated with the functional cytochrome b5 gene (CYB5A).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on cytochrome b5 type A pseudogene 3 (CYB5AP3).